Medarex Inc.

E. R. Squibb Sons, Inc.

Bristol-myers Squibb Compnay

Pfizer Corporation

Synthon B.v.

David B Passmore

Haichun Huang

Mohan Srinivasan

Josephine M Cardarelli

Changyu Wang

Alan J Korman

Mark J Selby

David J King

Alison Witte

Haibin Chen

Denise Leah Williams

Kristopher Toy

Arvind Rajpal

Brigitte Devaux

Peter Brams

Shrikant Deshpande

Chetana Rao-Naik

Dawn M Tanamachi

Lan Yang

Hans S Keirstead

Vangipuram S Rangan

Jun Zhang

Michael T Liu

Madhav Narasimha Devalaraja

Thomas E Lane

Edward L Halk

Heidi N Leblanc

Mark Yamanaka

Richard Theolis

Kyra D Zens

Lei Zhu

Asna Masood

Kent B Thuduim

Jenny Albanese

Sarah R Reed

Sanjeev Gangwar

Jie Liu

Vincent Guerlavais

Chin Pan

Amelia Nancy Black

Lynn F Dickey

Tim Sproul

Bilal Sufi

Charles G Peele

Liang Chen

Alasdair Fraser Bell

To Uyen Thi Do

Sharline Chen

Josphine M Cardelli

Kevin M Cox

David John King

Sara R Dwiggins

David King

Ming-Bo Wang

The present invention provides isolated monoclonal antibodies, particularly human antibodies, that bind to IP-10 with high affinity, inhibit the binding of IP-10 to its receptor, inhibit IP-10-induced calcium flux and inhibit IP-10-induced cell migration. Nucleic acid molecules encoding the antibodies of the invention, expression vectors, host cells and methods for expressing the antibodies of the invention are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting IP-10 activity using the antibodies of the invention, including methods for treating various inflammatory and autoimmune diseases.

IP-10 antibodies and their uses

The present invention provides isolated anti-interferon alpha monoclonal antibodies, particularly human monoclonal antibodies, that inhibit the biological activity of multiple interferon (IFN) alpha subtypes but do not substantially inhibit the biological activity of IFN alpha 21 or the biological activity of either IFN beta or IFN omega. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The invention also provides methods for inhibiting the biological activity of IFN alpha using the antibodies of the invention, as well as methods of treating disease or disorders mediated by IFN alpha, such as autoimmune diseases, transplant rejection and graft versus host disease, by administering the antibodies of the invention.

Methods for preparing interferon alpha antibodies

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-L1 antibodies.

Human monoclonal antibodies to programmed death ligand 1 (PD-L1)

The present disclosure provides isolated monoclonal antibodies that specifically bind to CD22 with high affinity, particularly human monoclonal antibodies. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Antibody-partner molecule conjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting CD22, as well as methods for treating various cancers and inflammatory and autoimmune disorders using an anti-CD22 antibody of this disclosure.

Human antibodies that bind CD22 and uses thereof

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to PD-L1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the invention are also provided. The disclosure also provides methods for detecting PD-L1, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-PD-LI antibodies.

Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions.

Antibodies to IL-6 and their uses

Nucleic acids encoding interferon alpha antibodies

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to BTLA with high affinity. Nucleic acid molecules encoding the antibodies of the disclosure, expression vectors, host cells and methods for expressing the antibodies of the disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of the disclosure are also provided. The disclosure also provides methods for detecting BTLA, as well as methods for treating various diseases, including cancer and infectious diseases, using anti-BTLA antibodies.

Human monoclonal antibodies to BTLA and methods of use

Interferon alpha antibodies and their uses

The present disclosure provides drug-ligand conjugates and drug-cleavable substrate conjugates that are potent cytotoxins. The disclosure is also directed to compositions containing the drug-ligand conjugates, and to methods of treatment using them.

Chemical linkers and cleavable substrates and conjugates thereof

The invention pertains to anti-PSMA antibodies that lack fucosyl residues. The antibodies of the invention exhibit increased antibody-dependent cellular cytotoxicity (ADCC) activity as compared to the fucosylated form of the antibodies. The invention also provides host cells that express the anti-PSMA antibodies that lack fucosyl residues, wherein the host cells are deficient for a fucosyl transferase. Methods of using the antibodies to inhibit the growth of PSMAcells, such as tumor cells, are also provided.

Monoclonal antibodies against prostate specific membrane antigen (PSMA) lacking in fucosyl residues

Growing community of inventors

San Carlos, CA, United States of America

David B Passmore